Real-time disaster intelligence, alerts, and response tools.
Thursday, April 23, 2026
[ad_1] TORL-1-23 Demonstrates Clinically Meaningful, Durable and Confirmed Responses with a Generally Manageable Safety Profile in Patients with Claudin 6 Positive (CLDN6+) Platinum-Resistant Ovarian Cancer Expansion Cohorts in Patients with Ovarian, Non-Small Cell Lung Cancer, […]
[ad_1] Adela’s tissue-agnostic MRD test has been clinically validated to predict and surveil for recurrence in patients with head & neck cancer, regardless of HPV status The test identified recurrences in head & neck cancer […]
[ad_1] Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease New results show potential of RYBREVANT® beyond lung cancer BARCELONA, Sept. 14, 2024 /PRNewswire/ — Johnson & Johnson (NYSE:JNJ) […]
[ad_1] STOCKHOLM, Sept. 13, 2024 /PRNewswire/ — Moberg Pharma AB (OMX: MOB) announces that the company has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for […]
[ad_1] TAIPEI, 12. September 2024 /PRNewswire/ — TCI Co. Ltd. („TCI”, 8436.TWO), seit über 40 Jahren ein weltweit führender Anbieter von ODM-Gesundheits- und Kosmetikprodukten, stellt seine innovative GLP-1-Formel vor, eine natürliche Mischung aus Pflanzenextrakten, Probiotika und […]
